Emergent BioSolutions (EBS)
Emergent BioSolutions on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, federal contracts, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
9.3M
Short interest
settlement 2026-09-30
8.3
Days to cover
-0.3 days vs prior
66.8%
Short share of volume
2026-10-23
616
Fails to deliver
settlement 2026-09-28
Wed 28 Oct
Next earnings
estimated date
-$146K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in EBS is 9,293,986 shares, down 1,548,249 shares over the last month. Over the last 48 readings it ranged from 6,812,370 shares (15 November 2024) to 11,640,558 shares (14 August 2026). At the reported average volume of 1.1M shares a day that is 8.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ebs" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 9,293,986 | -5.0% | 1,119,034 | 8.31 |
| 2026-09-15 | 9,786,380 | -9.7% | 1,138,009 | 8.60 |
| 2026-08-31 | 10,842,235 | -6.9% | 1,185,288 | 9.15 |
| 2026-08-14 | 11,640,558 | +16.1% | 1,940,233 | 6.00 |
| 2026-07-31 | 10,029,170 | -3.0% | 568,258 | 17.65 |
| 2026-07-15 | 10,339,037 | +0.7% | 785,751 | 13.16 |
| 2026-06-30 | 10,265,965 | +5.0% | 1,284,895 | 7.99 |
| 2026-06-15 | 9,772,053 | +0.1% | 761,981 | 12.82 |
| 2026-05-29 | 9,760,594 | +1.6% | 848,439 | 11.50 |
| 2026-05-15 | 9,604,080 | -1.8% | 800,704 | 11.99 |
| 2026-04-30 | 9,775,531 | +1.4% | 530,837 | 18.42 |
| 2026-04-15 | 9,643,974 | -0.1% | 712,776 | 13.53 |
| 2026-03-31 | 9,650,911 | +8.7% | 854,522 | 11.29 |
| 2026-03-13 | 8,875,813 | -1.2% | 1,204,218 | 7.37 |
| 2026-02-27 | 8,986,187 | +1.3% | 1,172,265 | 7.67 |
| 2026-02-13 | 8,870,355 | +2.9% | 649,265 | 13.66 |
| 2026-01-30 | 8,622,131 | -2.2% | 877,066 | 9.83 |
| 2026-01-15 | 8,818,514 | -3.4% | 1,048,105 | 8.41 |
| 2025-12-31 | 9,124,412 | +1.1% | 751,143 | 12.15 |
| 2025-12-15 | 9,020,934 | +1.2% | 866,145 | 10.42 |
| 2025-11-28 | 8,917,402 | -3.7% | 820,810 | 10.86 |
| 2025-11-14 | 9,260,505 | +12.7% | 1,226,264 | 7.55 |
| 2025-10-31 | 8,220,839 | -6.9% | 1,589,550 | 5.17 |
| 2025-10-15 | 8,830,216 | -8.1% | 865,855 | 10.20 |
| 2025-09-30 | 9,606,551 | +8.4% | 1,032,098 | 9.31 |
| 2025-09-15 | 8,857,827 | +1.7% | 965,872 | 9.17 |
| 2025-08-29 | 8,710,293 | -11.3% | 1,038,108 | 8.39 |
| 2025-08-15 | 9,815,705 | -1.3% | 1,746,883 | 5.62 |
| 2025-07-31 | 9,947,951 | +9.8% | 1,054,510 | 9.43 |
| 2025-07-15 | 9,056,841 | -9.5% | 1,124,235 | 8.06 |
| 2025-06-30 | 10,007,823 | +25.2% | 1,835,026 | 5.45 |
| 2025-06-13 | 7,991,534 | +2.0% | 859,299 | 9.30 |
| 2025-05-30 | 7,830,932 | -1.0% | 1,383,795 | 5.66 |
| 2025-05-15 | 7,911,368 | +2.0% | 1,451,782 | 5.45 |
| 2025-04-30 | 7,754,707 | -14.1% | 995,946 | 7.79 |
| 2025-04-15 | 9,024,472 | +0.6% | 1,210,557 | 7.45 |
| 2025-03-31 | 8,971,117 | -2.0% | 1,245,813 | 7.20 |
| 2025-03-14 | 9,156,033 | +12.5% | 1,753,005 | 5.22 |
| 2025-02-28 | 8,136,737 | +14.7% | 1,402,990 | 5.80 |
| 2025-02-14 | 7,094,646 | +2.4% | 813,956 | 8.72 |
| 2025-01-31 | 6,925,481 | -1.6% | 986,295 | 7.02 |
| 2025-01-15 | 7,040,698 | -1.3% | 989,095 | 7.12 |
| 2024-12-31 | 7,133,558 | +2.8% | 1,243,455 | 5.74 |
| 2024-12-13 | 6,936,897 | +0.1% | 897,456 | 7.73 |
| 2024-11-29 | 6,927,172 | +1.7% | 1,162,186 | 5.96 |
| 2024-11-15 | 6,812,370 | -2.0% | 1,993,145 | 3.42 |
| 2024-10-31 | 6,948,810 | -10.8% | 1,191,282 | 5.83 |
| 2024-10-15 | 7,791,409 | -5.3% | 1,419,557 | 5.49 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of EBS volume is 66.8%, up 5.2 points over the last five sessions. Over the last 30 readings it ranged from 37.9% (22 October 2026) to 87.0% (23 September 2026). The latest reading is 8.6 points above the 30-session average of 58.2%, on 210K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 140K | 210K | 66.8% | 0 |
| 2026-10-22 | 103K | 272K | 37.9% | 0 |
| 2026-10-21 | 182K | 323K | 56.4% | 901 |
| 2026-10-20 | 327K | 489K | 67.0% | 1 |
| 2026-10-19 | 261K | 389K | 67.0% | 28,261 |
| 2026-10-16 | 508K | 824K | 61.6% | 37,334 |
| 2026-10-15 | 139K | 226K | 61.4% | 0 |
| 2026-10-14 | 124K | 231K | 53.8% | 19 |
| 2026-10-13 | 139K | 213K | 65.2% | 0 |
| 2026-10-12 | 184K | 366K | 50.2% | 1,670 |
| 2026-10-09 | 176K | 305K | 57.6% | 1 |
| 2026-10-08 | 145K | 316K | 46.0% | 148 |
| 2026-10-07 | 254K | 514K | 49.5% | 2,354 |
| 2026-10-06 | 447K | 753K | 59.4% | 675 |
| 2026-10-05 | 544K | 1.0M | 54.0% | 4,300 |
| 2026-10-02 | 147K | 239K | 61.7% | 0 |
| 2026-10-01 | 222K | 339K | 65.5% | 511 |
| 2026-09-30 | 145K | 228K | 63.3% | 4 |
| 2026-09-29 | 139K | 258K | 53.7% | 6,144 |
| 2026-09-28 | 142K | 292K | 48.7% | 5,546 |
| 2026-09-25 | 133K | 286K | 46.6% | 933 |
| 2026-09-24 | 220K | 372K | 59.3% | 43 |
| 2026-09-23 | 405K | 466K | 87.0% | 0 |
| 2026-09-22 | 213K | 450K | 47.4% | 14,377 |
| 2026-09-21 | 254K | 586K | 43.3% | 0 |
| 2026-09-18 | 229K | 335K | 68.6% | 737 |
| 2026-09-17 | 372K | 541K | 68.7% | 0 |
| 2026-09-16 | 360K | 629K | 57.2% | 3,840 |
| 2026-09-15 | 188K | 341K | 55.1% | 10 |
| 2026-09-14 | 180K | 272K | 66.1% | 2,156 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 28 September 2026, the fails-to-deliver balance in EBS is 616 shares, up 137 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (31 July 2026) to 515,849 shares (23 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-28 | 616 | $6.79 | $4K |
| 2026-09-23 | 479 | $6.76 | $3K |
| 2026-09-21 | 16,303 | $6.80 | $111K |
| 2026-09-18 | 4,246 | $7.02 | $30K |
| 2026-09-17 | 223 | $6.75 | $2K |
| 2026-09-14 | 414 | $6.23 | $3K |
| 2026-09-08 | 415 | $6.21 | $3K |
| 2026-09-04 | 24,966 | $6.23 | $156K |
| 2026-09-03 | 31,398 | $6.46 | $203K |
| 2026-09-02 | 2 | $6.22 | $12 |
| 2026-09-01 | 7,737 | $6.10 | $47K |
| 2026-08-28 | 3 | $5.94 | $18 |
| 2026-08-24 | 105 | $5.08 | $533 |
| 2026-08-20 | 1,414 | $4.89 | $7K |
| 2026-08-12 | 103 | $4.45 | $458 |
| 2026-08-05 | 483 | $7.57 | $4K |
| 2026-08-04 | 33 | $7.41 | $245 |
| 2026-07-31 | 1 | $7.26 | $7 |
| 2026-07-29 | 2,643 | $7.31 | $19K |
| 2026-07-24 | 1,402 | $7.50 | $11K |
| 2026-07-16 | 340 | $7.89 | $3K |
| 2026-07-02 | 147 | $8.28 | $1K |
| 2026-06-25 | 261 | $8.43 | $2K |
| 2026-06-23 | 515,849 | $7.85 | $4.0M |
| 2026-06-18 | 33 | $8.14 | $269 |
| 2026-06-16 | 579 | $8.29 | $5K |
| 2026-06-15 | 1,649 | $8.32 | $14K |
| 2026-06-09 | 347 | $8.00 | $3K |
| 2026-06-05 | 599 | $8.44 | $5K |
| 2026-06-02 | 1,568 | $8.49 | $13K |
Insider trades
SEC Form 4, newest first. JSONInsiders at EBS reported 2 open-market sells worth $146K in the last 90 days and no open-market buys. Latest filing: DeGolyer Donald W (Director) on 2026-10-07.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | DeGolyer Donald W | Director | Sell | 18K | $7.09 | $126K | 112K |
| 2026-10-01 | Williams Paul Anthony | SVP, Products Business | Sell | 3K | $6.53 | $20K | 156K |
| 2026-07-01 | Williams Paul Anthony | SVP, Products Business | Sell | 3K | $8.40 | $25K | 159K |
| 2026-06-08 | Hartzel William | SVP, Bioservices | Tax withholding | 2K | $8.00 | $14K | 186K |
| 2026-06-08 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 694 | $8.00 | $6K | 162K |
| 2026-06-08 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 2K | $8.00 | $16K | 202K |
| 2026-06-08 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 4K | $8.00 | $32K | 374K |
| 2026-05-01 | Zoon Kathryn C | Director | Sell | 1K | $8.97 | $9K | 80K |
| 2026-05-01 | Zoon Kathryn C | Director | Sell | 16K | $8.36 | $135K | 81K |
| 2026-05-01 | DeGolyer Donald W | Director | Sell | 954 | $8.96 | $9K | 130K |
| 2026-05-01 | DeGolyer Donald W | Director | Sell | 15K | $8.36 | $121K | 131K |
| 2026-05-01 | Dayal Sujata Tyagi | Director | Sell | 980 | $8.94 | $9K | 101K |
| 2026-05-01 | Dayal Sujata Tyagi | Director | Sell | 13K | $8.36 | $107K | 102K |
| 2026-04-30 | Zoon Kathryn C | Director | Grant | 25K | $0.00 | $0 | 97K |
| 2026-04-30 | Fowler Neal Franklin | Director | Grant | 25K | $0.00 | $0 | 161K |
| 2026-04-30 | White Marvin L | Director | Grant | 25K | $0.00 | $0 | 114K |
| 2026-04-30 | Harsanyi Zsolt | Chairman | Grant | 25K | $0.00 | $0 | 149K |
| 2026-04-30 | Richard Ronald | Director | Grant | 25K | $0.00 | $0 | 124K |
| 2026-04-30 | Katkin Keith | Director | Sell | 15K | $8.28 | $128K | 96K |
| 2026-04-30 | Katkin Keith | Director | Grant | 25K | $0.00 | $0 | 112K |
| 2026-04-30 | FOWLER JOHN D JR | Director | Grant | 25K | $0.00 | $0 | 30K |
| 2026-04-30 | DeGolyer Donald W | Director | Grant | 25K | $0.00 | $0 | 145K |
| 2026-04-30 | Dayal Sujata Tyagi | Director | Grant | 25K | $0.00 | $0 | 114K |
| 2026-04-29 | Lowry Simon C | SVP, R&D, CMO | Grant | 100K | $0.00 | $0 | 178K |
| 2026-04-29 | Perl Jessica | SVP, General Counsel, Corp Sec | Grant | 104K | $0.00 | $0 | 165K |
| 2026-04-29 | Hartzel William | SVP, Bioservices | Grant | 100K | $0.00 | $0 | 187K |
| 2026-04-29 | Williams Paul Anthony | SVP, Products Business | Grant | 100K | $0.00 | $0 | 163K |
| 2026-04-29 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Grant | 100K | $0.00 | $0 | 204K |
| 2026-04-29 | PAPA JOSEPH C | President and CEO | Grant | 188K | $0.00 | $0 | 493K |
| 2026-04-29 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Grant | 163K | $0.00 | $0 | 378K |
| 2026-04-01 | Williams Paul Anthony | SVP, Products Business | Sell | 4K | $8.44 | $34K | 63K |
| 2026-03-05 | Lowry Simon C | SVP, R&D, CMO | Tax withholding | 11K | $8.44 | $90K | 78K |
| 2026-03-05 | Perl Jessica | SVP, General Counsel, Corp Sec | Tax withholding | 6K | $8.44 | $55K | 61K |
| 2026-03-05 | Hartzel William | SVP, Bioservices | Tax withholding | 9K | $8.44 | $80K | 87K |
| 2026-03-05 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 9K | $8.44 | $79K | 67K |
| 2026-03-05 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 8K | $8.44 | $69K | 104K |
| 2026-03-05 | PAPA JOSEPH C | President and CEO | Tax withholding | 37K | $8.44 | $313K | 305K |
| 2026-03-05 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 24K | $8.44 | $200K | 215K |
| 2026-03-03 | FOWLER JOHN D JR | Director | Grant | 5K | $8.99 | $45K | 5K |
| 2026-03-01 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 116 | $8.15 | $945 | 76K |
| 2026-03-01 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 313 | $8.15 | $3K | 112K |
| 2026-03-01 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 683 | $8.15 | $6K | 239K |
| 2026-02-09 | Perl Jessica | SVP, General Counsel, Corp Sec | Tax withholding | 918 | $11.03 | $10K | 67K |
| 2026-02-06 | Hartzel William | SVP, Bioservices | Tax withholding | 630 | $10.92 | $7K | 97K |
| 2026-02-06 | Hartzel William | SVP, Bioservices | Returned to company | 6K | $10.92 | $63K | 97K |
| 2026-02-06 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 1K | $10.92 | $11K | 76K |
| 2026-02-06 | Williams Paul Anthony | SVP, Products Business | Returned to company | 9K | $10.92 | $95K | 77K |
| 2026-02-06 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 3K | $10.92 | $31K | 113K |
| 2026-02-06 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Returned to company | 29K | $10.92 | $315K | 115K |
| 2026-02-06 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 6K | $10.92 | $62K | 240K |
| 2026-02-06 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Returned to company | 46K | $10.92 | $504K | 245K |
| 2025-12-14 | Lowry Simon C | SVP, R&D, CMO | Tax withholding | 4K | $11.41 | $40K | 88K |
| 2025-12-05 | Richard Ronald | Director | Sell | 15K | $11.90 | $177K | 98K |
| 2025-12-05 | Richard Ronald | Director | Tax withholding | 11K | $11.90 | $129K | 113K |
| 2025-12-05 | Richard Ronald | Director | Exercise or conversion | 26K | $5.02 | $129K | 124K |
| 2025-12-05 | Richard Ronald | Director | Sell | 7K | $12.11 | $86K | 98K |
| 2025-11-11 | Hartzel William | SVP, Bioservices | Tax withholding | 610 | $10.88 | $7K | 103K |
| 2025-11-10 | DeGolyer Donald W | Director | Sell | 18K | $10.54 | $188K | 120K |
| 2025-11-07 | Dayal Sujata Tyagi | Director | Sell | 9K | $10.00 | $86K | 89K |
| 2025-10-15 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 5K | $9.60 | $48K | 291K |
| 2025-10-07 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Sell | 31K | $10.00 | $306K | 144K |
| 2025-08-15 | Zoon Kathryn C | Director | Sell | 7K | $8.87 | $63K | 72K |
| 2025-08-12 | DeGolyer Donald W | Director | Sell | 8K | $8.65 | $68K | 138K |
| 2025-07-11 | Hartzel William | SVP, Bioservices | Tax withholding | 4K | $7.36 | $31K | 104K |
| 2025-06-08 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 3K | $6.63 | $18K | 296K |
| 2025-06-08 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 464 | $6.63 | $3K | 86K |
| 2025-06-08 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 1K | $6.63 | $8K | 175K |
| 2025-06-08 | Hartzel William | SVP, Bioservices | Tax withholding | 1K | $6.63 | $8K | 108K |
| 2025-05-23 | Katkin Keith | Director | Sell | 8K | $6.30 | $49K | 86K |
| 2025-05-13 | PAPA JOSEPH C | President and CEO | Buy | 60K | $5.83 | $350K | 343K |
| 2025-04-30 | SULLIVAN LOUIS W | Director | Grant | 34K | $0.00 | $0 | 139K |
| 2025-04-30 | DeGolyer Donald W | Director | Grant | 34K | $0.00 | $0 | 146K |
| 2025-04-30 | Harsanyi Zsolt | Chairman | Grant | 34K | $0.00 | $0 | 124K |
| 2025-04-30 | Katkin Keith | Director | Grant | 34K | $0.00 | $0 | 94K |
| 2025-04-30 | Dayal Sujata Tyagi | Director | Grant | 34K | $0.00 | $0 | 98K |
| 2025-04-30 | Zoon Kathryn C | Director | Grant | 34K | $0.00 | $0 | 79K |
| 2025-04-30 | Fowler Neal Franklin | Director | Grant | 34K | $0.00 | $0 | 136K |
| 2025-04-30 | White Marvin L | Director | Grant | 34K | $0.00 | $0 | 88K |
| 2025-04-30 | Richard Ronald | Director | Grant | 34K | $0.00 | $0 | 106K |
| 2025-04-07 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 480 | $4.44 | $2K | 176K |
| 2025-04-07 | Hartzel William | SVP, Bioservices | Tax withholding | 561 | $4.44 | $2K | 109K |
| 2025-03-12 | Zoon Kathryn C | Director | Sell | 10K | $5.73 | $57K | 44K |
| 2025-03-12 | Fowler Neal Franklin | Director | Sell | 35K | $5.83 | $204K | 101K |
| 2025-03-06 | Hartzel William | SVP, Bioservices | Grant | 63K | $0.00 | $0 | 110K |
| 2025-03-06 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Grant | 63K | $0.00 | $0 | 177K |
| 2025-03-06 | PAPA JOSEPH C | President and CEO | Grant | 283K | $0.00 | $0 | 283K |
| 2025-03-06 | Hartzel William | SVP, Bioservices | Grant | 63K | $0.00 | $0 | 110K |
| 2025-03-06 | Lowry Simon C | SVP, R&D, CMO | Grant | 63K | $0.00 | $0 | 92K |
| 2025-03-06 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Grant | 147K | $0.00 | $0 | 299K |
| 2025-03-06 | Williams Paul Anthony | SVP, Products Business | Grant | 63K | $0.00 | $0 | 86K |
| 2025-03-06 | Perl Jessica | SVP, General Counsel, Corp Sec | Grant | 63K | $0.00 | $0 | 68K |
| 2025-03-05 | Hartzel William | SVP, Bioservices | Tax withholding | 292 | $5.80 | $2K | 47K |
| 2025-03-01 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 683 | $7.48 | $5K | 152K |
| 2025-03-01 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 116 | $7.48 | $868 | 24K |
| 2025-03-01 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Tax withholding | 313 | $7.48 | $2K | 114K |
| 2025-02-28 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Tax withholding | 1K | $7.48 | $8K | 153K |
| 2025-02-28 | Williams Paul Anthony | SVP, Products Business | Tax withholding | 382 | $7.48 | $3K | 24K |
| 2025-02-12 | LINDAHL RICHARD S | EVP, Chief Financial Officer | Returned to company | 17K | $0.00 | $0 | 154K |
| 2025-02-12 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Returned to company | 6K | $0.00 | $0 | 139K |
| 2025-02-12 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Returned to company | 24K | $0.00 | $0 | 114K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON14 Form 144 notices on file for EBS worth $3.4M at the prices reported; 2 in the last 90 days worth $146K. Latest: DONALD DEGOLYER filed on 2026-10-07 to sell 17,800 shares ($126K) from 2026-10-07.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-07 | DONALD DEGOLYERDirector | 18K | $126K | 0.035% | 2026-10-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-01 | PAUL WILLIAMSOfficer | 3K | $20K | 0.006% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | PAUL WILLIAMSOfficer | 3K | $25K | 0.006% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | KATHRYN ZOONDirector | 17K | $144K | 0.033% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | DONALD DEGOLYERDirector | 15K | $130K | 0.030% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | SUJATA TYAGI DAYALDirector | 14K | $116K | 0.027% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-30 | KEITH KATKINDirector | 15K | $128K | 0.030% | 2026-04-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | PAUL WILLIAMSOfficer | 4K | $34K | 0.008% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-07 | LOUIS W SULLIVANDirector | 26K | $360K | 0.049% | 2026-01-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-22 | LOUIS W SULLIVANDirector | 105K | $1.3M | 0.199% | 2025-12-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-05 | RONALD RICHARDDirector | 33K | $392K | 0.063% | 2025-12-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-10 | DONALD DEGOLYERDirector | 18K | $188K | 0.034% | 2025-11-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-07 | SUJATA TYAGI DAYALDirector | 9K | $86K | 0.016% | 2025-11-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-07 | COLEEN GLESSNEROfficer | 31K | $306K | 0.057% | 2025-10-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of EBS in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 9.0% of the class (4,651,339 shares), filed 2026-07-28 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-31 | 13G/Ano. 1 | Vanguard Capital Managementinvestment adviser | 2.5M | 4.9% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 4.7M | 9.0% | 2026-06-30 |
| 2026-04-09 | 13G | Dimensional Fund Advisors LPinvestment adviser | 2.8M | 5.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 15 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-09 | 13G | STATE STREET CORPORATIONparent holding company | 2.7M | 5.1% | 2025-12-31 |
13F holders
Tracked managers holding EBS at their latest 13F. JSON5 of the 30 tracked managers held EBS at their latest 13F, $35.1M in total at quarter-end prices. Millennium Management is the largest at $9.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.1M | $9.0M | 0.00% | +540K |
| AQR Capital Management | 2026-06-30 | 1.0M | $8.7M | 0.00% | +51K |
| D. E. Shaw & Co. | 2026-06-30 | 900K | $7.5M | 0.00% | -104K |
| Renaissance Technologies | 2026-06-30 | 683K | $5.7M | 0.01% | +27K |
| Two Sigma Investments | 2026-06-30 | 488K | $4.1M | 0.00% | -89K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Emergent BioSolutions reported revenue of $234.3M, up 66.3% from the same quarter a year earlier, and net loss of $180.2M (-3.49 diluted EPS). In FY 2025 it generated $170.6M of operating cash flow and spent $24.9M on buybacks. As of 2026-06-30, cash was $139.7M against $589.7M of debt.
- Cash
- $139.7M
- Debt
- $589.7M
- Equity
- $341.4M
- Total assets
- $1.12B
- Shares outstanding
- 51,273,336
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $234.3M | -$180.2M | -76.9% | -3.49 |
| Q1 FY 2026 | 2026-03-31 | $156.1M | $6.8M | 4.4% | 0.07 |
| Q4 FY 2025derived | 2025-12-31 | $148.7M | -$54.6M | -36.7% | n/a |
| Q3 FY 2025 | 2025-09-30 | $231.1M | $51.2M | 22.2% | 0.91 |
| Q2 FY 2025 | 2025-06-30 | $140.9M | -$12.0M | -8.5% | -0.22 |
| Q1 FY 2025 | 2025-03-31 | $222.2M | $68.0M | 30.6% | 1.19 |
| Q4 FY 2024derived | 2024-12-31 | $194.7M | -$31.3M | -16.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $293.8M | $114.8M | 39.1% | 2.06 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $742.9M | $52.6M | $170.6M | $13.8M | $24.9M | n/a |
| FY 2024 | 2024-12-31 | $1.04B | -$190.6M | $58.7M | $22.9M | $0 | n/a |
| FY 2023 | 2023-12-31 | $1.05B | -$760.5M | -$206.3M | $51.6M | $0 | n/a |
| FY 2022 | 2022-12-31 | $1.12B | -$211.6M | -$34.1M | $115.8M | $82.1M | n/a |
| FY 2021 | 2021-12-31 | $1.77B | $219.5M | $320.2M | $224.1M | $106.0M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
Federal contracts
The largest contract actions for Emergent BioSolutions and its subsidiaries. JSON1 contract action on file for EBS: $0 obligated in the last 90 days and $2.4M in the last 12 months across 1 awarding agency. The largest was $2.4M from the Department of Health and Human Services on 2026-07-08 (no cost mod to extend the pop for clin0001 through august 28, 2031. exercise and fully fund opt clin0005b for the procur...). This covers the largest contract actions, not every award, and agencies report late.
| Action date | Agency | Amount | Type | Description |
|---|---|---|---|---|
| 2026-07-08 | Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | $2.4M | mod P00009definitive contract | NO COST MOD TO EXTEND THE POP FOR CLIN0001 THROUGH AUGUST 28, 2031. EXERCISE AND FULLY FUND OPT CLIN0005B FOR THE PROCUREMENT OF 4,896 ORAL SUSPENSION TREATMENT COURSES IN THE AMOUNT OF $2,360,280.00. UPDATE G.1. CO. UPDATE G.3. CONTRACTOR'S POIUSAspending |
What this page is
Emergent BioSolutions in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Emergent BioSolutions (EBS), SEC CIK 1367644, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-28.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-07.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-31.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Federal contracts
- USAspending.govSource: USAspending.gov.The largest contract actions each day, as agencies report them (up to 90 days late). Latest 2026-07-08.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-07.JSON and CSV
- Company record
- EDGAR filing index for CIK 1367644Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of EBS is sold short?
9,293,986 shares were held short at the 2026-09-30 settlement, 8.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is EBS's daily short volume?
On 2026-10-23, 140,145 of the 209,856 EBS shares reported to FINRA were sold short, 66.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does EBS have fails to deliver?
The SEC's latest file shows 616 EBS shares failed to deliver at settlement 2026-09-28. Fails are reported per settlement date and published twice a month with a lag.
Are EBS insiders buying or selling?
Insiders at EBS reported 2 open-market sells worth $146K in the last 90 days and no open-market buys. Latest filing: DeGolyer Donald W (Director) on 2026-10-07.
Have EBS insiders filed to sell?
14 Form 144 notices on file for EBS worth $3.4M at the prices reported; 2 in the last 90 days worth $146K. Latest: DONALD DEGOLYER filed on 2026-10-07 to sell 17,800 shares ($126K) from 2026-10-07.
Who owns 5% or more of EBS?
3 holders report 5% or more of EBS in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 9.0% of the class (4,651,339 shares), filed 2026-07-28 for an event on 2026-06-30.
What did EBS report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Emergent BioSolutions reported revenue of $234.3M, up 66.3% from the same quarter a year earlier, and net loss of $180.2M (-3.49 diluted EPS). In FY 2025 it generated $170.6M of operating cash flow and spent $24.9M on buybacks. As of 2026-06-30, cash was $139.7M against $589.7M of debt.
Which tracked 13F managers own EBS?
5 of the 30 tracked 13F managers held EBS shares at their latest filing, $35.1M in all. The largest: Izzy Englander's Millennium Management (1.1M shares, $9.0M), Cliff Asness's AQR Capital Management (1.0M shares, $8.7M), D. E. Shaw & Co. (900K shares, $7.5M), Renaissance Technologies (683K shares, $5.7M), Two Sigma Investments (488K shares, $4.1M).
How much federal contract money did EBS receive?
$0 was obligated to Emergent BioSolutions and its subsidiaries in the last 90 days and $2.4M in the last 12 months, counting the largest contract actions on USAspending, not every award. Obligations are not revenue; they are spent over each contract's life.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.